Synergy Asset Management LLC Sells 245,213 Shares of Boston Scientific Corporation $BSX

Synergy Asset Management LLC cut its position in Boston Scientific Corporation (NYSE:BSX) by 49.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 248,110 shares of the medical equipment provider’s stock after selling 245,213 shares during the quarter. Boston Scientific makes up approximately 2.5% of Synergy Asset Management LLC’s investment portfolio, making the stock its 11th largest holding. Synergy Asset Management LLC’s holdings in Boston Scientific were worth $23,657,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Norges Bank bought a new position in shares of Boston Scientific during the 2nd quarter worth approximately $2,089,937,000. Edgewood Management LLC acquired a new stake in Boston Scientific in the second quarter valued at approximately $746,655,000. Parnassus Investments LLC grew its holdings in Boston Scientific by 42,978.9% in the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after purchasing an additional 6,868,459 shares during the last quarter. Egerton Capital UK LLP increased its position in shares of Boston Scientific by 223.7% during the third quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock worth $518,660,000 after purchasing an additional 3,671,548 shares in the last quarter. Finally, Jennison Associates LLC lifted its holdings in shares of Boston Scientific by 133.5% during the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock valued at $482,170,000 after purchasing an additional 2,823,744 shares during the last quarter. 89.07% of the stock is owned by hedge funds and other institutional investors.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $70.08 on Friday. Boston Scientific Corporation has a twelve month low of $67.56 and a twelve month high of $109.50. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The company has a market cap of $104.16 billion, a PE ratio of 36.13, a price-to-earnings-growth ratio of 1.08 and a beta of 0.69. The company’s 50 day moving average is $77.83 and its 200 day moving average is $91.10.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same period in the prior year, the firm earned $0.70 EPS. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.50% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Some analysts and commentators see a potential turn in fortunes or an eventual rating upgrade if execution improves, which supports a constructive long‑term thesis for BSX. Boston Scientific: Under Pressure, But Could See A Shift In Fortunes (Rating Upgrade)
• Neutral Sentiment: Analyst model adjustments have been modest — Erste trimmed a FY2027 EPS forecast slightly — indicating analysts are tightening growth assumptions rather than making sweeping downgrades. This is a modest headwind but not a major re‑rating event by itself.
• Negative Sentiment: Multiple law firms have filed or solicited plaintiffs in securities class actions alleging misstatements about U.S. electrophysiology procedure growth and related disclosures; the cases cover purchases from July 23, 2025 through Feb 3, 2026 and highlight a May 4, 2026 lead‑plaintiff deadline. This clustering increases legal and settlement risk and is weighing on the stock. BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit
• Negative Sentiment: Several other firms issued investor alerts and lawsuits (Pomerantz, Portnoy, Bernstein Liebhard, Levi & Korsinsky, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Robbins Geller, etc.), reinforcing the coverage and media attention around litigation risk and potential shareholder losses. BSX Investor Alert: Securities Fraud Lawsuit (SueWallSt)
• Negative Sentiment: Market coverage of these developments coincided with recent share weakness and headlines noting sharper-than-market declines, which can amplify short‑term selling pressure as investors de‑risk exposure. Boston Scientific (BSX) Falls More Steeply Than Broader Market

Analysts Set New Price Targets

Several brokerages recently issued reports on BSX. Stifel Nicolaus reduced their target price on Boston Scientific from $110.00 to $90.00 and set a “buy” rating on the stock in a research report on Friday, March 20th. Royal Bank Of Canada cut their price objective on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. TD Cowen lowered their target price on shares of Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Needham & Company LLC restated a “buy” rating and set a $97.00 price target on shares of Boston Scientific in a research note on Friday, March 20th. Finally, Robert W. Baird lowered their price objective on shares of Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $106.27.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.